{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:09:45Z","timestamp":1771625385065,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.transci.2020.103011","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T02:15:10Z","timestamp":1604715310000},"page":"103011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI)"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-4508","authenticated-orcid":false,"given":"Joan","family":"Cid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Isabel","family":"P\u00e9rez-Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Torrente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"\u00c1varez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maribel","family":"D\u00edaz-Ricart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2020.103011_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.transci.2020.103011_bib0010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MOH.0000000000000169","article-title":"ADAMTS13 and von Willebrand factor interactions","volume":"22","author":"Zander","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.transci.2020.103011_bib0015","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc NY Pathol Soc"},{"key":"10.1016\/j.transci.2020.103011_bib0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2020.103011_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic Purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.transci.2020.103011_bib0030","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2020.103011_bib0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"51","key":"10.1016\/j.transci.2020.103011_bib0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.transci.2014.08.018","article-title":"Efficacy and safety of plasma exchange: an 11-year single-center experience of 2730 procedures in 317 patients","author":"Cid","year":"2014","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2020.103011_bib0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2020.103011_bib0050","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1538-7836.2006.01904.x","article-title":"Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods","volume":"4","author":"Kremer Hovinga","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2020.103011_bib0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1526-0968.2002.00297.x","article-title":"The effectiveness of intravenous human immunoglobulin treatment after plasmapheresis in restoring serum immunoglobulin levels: a preliminary study","volume":"6","author":"Moriya","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.transci.2020.103011_bib0060","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2020.103011_bib0065","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.103011_bib0070","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2020.103011_bib0075","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2020.103011_bib0080","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jca.21288","article-title":"The use of 50% albumin\/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura","volume":"28","author":"O\u2019Brien","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2020.103011_bib0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jca.21475","article-title":"Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma","volume":"32","author":"Sidhu","year":"2017","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2020.103011_bib0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/jca.21771","article-title":"Efficacy of albumin and compounded plasma for plasma exchange in acquired thrombotic thrombocytopenic purpura","volume":"35","author":"Hou","year":"2020","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2020.103011_bib0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21325","article-title":"Successful management of thrombotic thrombocytopenic purpura in a Jehovah\u2019s Witness without plasma exchange","volume":"30","author":"Chai","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2020.103011_bib0100","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/bloodadvances.2017012351","article-title":"Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah\u2019s Witness experience","volume":"1","author":"George","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2020.103011_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25715","article-title":"Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab","author":"Sukumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2020.103011_bib0110","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/trf.15823","article-title":"Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma","volume":"60","author":"Irani","year":"2020","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.transci.2020.103011_bib0115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.autrev.2011.04.028","article-title":"Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature","volume":"10","author":"Pons-Estel","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.transci.2020.103011_bib0120","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.103011_bib0125","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/trf.14193","article-title":"Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial","volume":"57","author":"Uhl","year":"2017","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.transci.2020.103011_bib0130","series-title":"Blood banking and transfusion medicine basic principles & practice","first-page":"738","article-title":"Therapeutic plasma exchange","author":"McLeod","year":"2007"},{"key":"10.1016\/j.transci.2020.103011_bib0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0000000000000933","article-title":"Preconditioning therapy in ABO-Incompatible living kidney transplantation: a systematic review and meta-analysis","volume":"100","author":"Lo","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transci.2020.103011_bib0140","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transci.2020.103011_bib0145","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","article-title":"The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review","volume":"94","author":"Roberts","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transci.2020.103011_bib0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ctr.12491","article-title":"Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey","volume":"29","author":"Burton","year":"2015","journal-title":"Clin Transplant"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220303347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220303347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:52:52Z","timestamp":1761468772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050220303347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1473050220303347"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2020.103011","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI)","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2020.103011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103011"}}